DexCom (DXCM) is down about 3% in Friday trading, reflecting ongoing pressure from a growth-and-margin narrative that has stayed negative since the company outlined a cautious 2026 setup that included a projected sequential revenue decline in Q1 and full-year guidance that disappointed investors. That outlook remains the dominant explanation for modest selloffs on down days, particularly when there is no fresh product or regulatory catalyst to offset concerns. (tipranks.com)

The stock’s reaction function has been unusually twitchy because the debate is no longer just about CGM category growth, but about DexCom’s competitive position and execution. A key bearish framing has been that Abbott’s FreeStyle Libre is pressing into DexCom’s core segments, while DexCom has had to manage quality-related scrutiny and costs—factors that can compress margins and complicate share gains even when demand is healthy. (in.investing.com)

The next major catalyst is DexCom’s first-quarter 2026 earnings report, scheduled for after the market close on Thursday, April 30, 2026. With sentiment already leaning cautious, investors are likely to focus on: (1) whether Q1 demand tracks the implied sequential dip, (2) gross margin progression and any quality-cost headwinds, and (3) evidence that newer offerings and pipeline initiatives can re-accelerate growth through the rest of 2026. (quantisnow.com)